After spending more than two years in stealth mode, Sionna Therapeutics is unveiling with $111 million in series B funds to catapult its cystic fibrosis pipeline and take on market leader Vertex ...

Two biotechnology startups on Friday revealed plans to launch initial public offerings, extending a step-up in IPO activity among privately held drug companies. Sionna Therapeutics is working on ...

Vertex Pharmaceuticals dominates the market for cystic fibrosis drugs, but Sionna Therapeutics contends the pharma company’s products still have efficacy and safety limitations. Sionna has mapped out ...

Sionna Therapeutics, Inc. (NASDAQ:SION) released data from its Phase 1 trials of SION-719 and SION-451, the company’s first-in-class nucleotide-binding domain 1 (NBD1) stabilizers, in healthy ...

WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics (SION), Inc. , a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic ...

Following these transactions, the involved parties now hold a total of 6,684,962 shares of Sionna Therapeutics' common stock. This strategic move reflects TPG's continued interest and investment in ...

WALTHAM, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for ...

Phase 1 MAD dosing completed for SION-451 and final MAD cohort of SION-719 planned; Interim data in healthy volunteers show potential to provide clinically meaningful benefit to CF patients. Topline ...

On track to initiate Phase 2a proof-of-concept trial and at least one dual combination MAD trial in the second half of 2025; topline data for both anticipated in mid-2026 Strong cash position ...

Following these transactions, the involved parties now hold a total of 6,684,962 shares of Sionna Therapeutics’ common stock. This strategic move reflects TPG’s continued interest and investment in ...